Advertisement
Educational review| Volume 84, ISSUE 2, P197-215, August 2007

Download started.

Ok

Evidence-based radiation oncology: Definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer

      Abstract

      The standard treatment options based on the risk category (stage, Gleason score, PSA) for localized prostate cancer include surgery, radiotherapy and watchful waiting. The literature does not provide clear-cut evidence for the superiority of surgery over radiotherapy, whereas both approaches differ in their side effects. The definitive external beam irradiation is frequently employed in stage T1b–T1c, T2 and T3 tumors. There is a pretty strong evidence that intermediate- and high-risk patients benefit from dose escalation. The latter requires reduction of the irradiated normal tissue (using 3-dimensional conformal approach, intensity modulated radiotherapy, image-guided radiotherapy, etc.). Recent data suggest that prostate cancer may benefit from hypofractionation due to relatively low α/β ratio; these findings warrant confirmation though. The role of whole pelvis irradiation is still controversial. Numerous randomized trials demonstrated a clinical benefit in terms of biochemical control, local and distant control, and overall survival from the addition of androgen suppression to external beam radiotherapy in intermediate- and high-risk patients. These studies typically included locally advanced (T3–T4) and poor-prognosis (Gleason score >7 and/or PSA >20 ng/mL) tumors and employed neoadjuvant/concomitant/adjuvant androgen suppression rather than only adjuvant setting. The ongoing trials will hopefully further define the role of endocrine treatment in more favorable risk patients and in the setting of the dose escalated radiotherapy.
      Brachytherapy (BRT) with permanent implants may be offered to low-risk patients (cT1–T2a, Gleason score <7, or 3 + 4, PSA ⩽10 ng/mL), with prostate volume of ⩽50 ml, no previous transurethral prostate resection and a good urinary function. Some recent data suggest a benefit from combining external beam irradiation and BRT for intermediate-risk patients.
      EBRT after radical prostatectomy improves disease-free survival and biochemical and local control rates in patients with positive surgical margins or pT3 tumors. Salvage radiotherapy may be considered at the time of biochemical failure in previously non-irradiated patients.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Radiotherapy and Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Adams E.J.
        • Convery D.J.
        • Cosgrove V.P.
        • et al.
        Clinical implementation of dynamic and step-and-shoot IMRT to treat prostate cancer with high risk of pelvic lymph node involvement.
        Radiother Oncol. 2004; 70: 1-10
        • Akakura K.
        • Isaka S.
        • Akimoto S.
        • et al.
        Long-term results of randomized trial for the stages B2 and C prostate cancer: radical prostatectomy versus external beam radiation therapy with a common endocrine therapy in both modalities.
        Urology. 1999; 54: 313-318
        • Akimoto T.
        • Katoh H.
        • Kitamoto Y.
        • et al.
        Rectal bleeding after high-dose-rate brachytherapy combined with hypofractionated external-beam radiotherapy for localized prostate cancer: impact of rectal dose in high-dose-rate brachytherapy on occurrence of grade 2 or worse rectal bleeding.
        Int J Radiat Oncol Biol Phys. 2006; 65: 364-370
      1. American Society for Therapeutic Radiology and Oncology: Consensus statement: guidelines for PSA following radiation therapy – American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys 1997;37:1035–41.

        • Aristizabal S.A.
        • Steinbronn D.
        • Heusinkveld R.S.
        External beam radiotherapy in cancer of the prostate. The university of Arizona experience.
        Radiother Oncol. 1984; 1: 309-315
        • Asbell S.O.
        • Krall J.M.
        • Pipelich M.V.
        • et al.
        Elective pelvic irradiation in stage A2, B carcinoma of the prostate: analysis of RTOG 77-06.
        Int J Radiat Oncol Biol Phys. 1988; 15: 1307-1316
        • Asbell S.O.
        • Martz K.L.
        • Shin K.H.
        • et al.
        Impact of surgical staging in evaluating the radiotherapeutic outcome in RTOP 77-06, a phase III study for T1bN0M0 (A2) and T2N0M0 (B) prostate carcinoma.
        Int J Radiat Oncol Biol Phys. 1988; 40: 769-782
        • Ash D.
        • Flynn A.
        • Batterman J.
        • de Reijke T.
        • Lavagnini P.
        • Blank L.
        • ESTRO/EAU Urological Brachytherapy Group; EORTC Radiotherapy Group
        ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer.
        Radiother Oncol. 2000; 57: 315-321
        • Aus G.
        Current status of HIFU and cryotherapy in prostate cancer – a review.
        Eur Urol. 2006; 50: 927-934
        • Aus G.
        • Abbou C.C.
        • Bolla M.
        • et al.
        EAU guidelines on prostate cancer.
        Eur Urol. 2005; 48: 546-551
        • Bagshaw M.A.
        Radiotherapeutic treatment of prostatic carcinoma with pelvic node involvement.
        Urol Clin North Am. 1984; 11: 297-304
        • Battermann J.J.
        • Boon T.A.
        • Moerland M.A.
        Results of permanent prostate brachytherapy, 13 years of experience at a single institution.
        Radiother Oncol. 2004; 71: 23-28
        • Baum C.
        • Alber M.
        • Birkner M.
        • Nusslin F.
        Robust treatment planning for intensity modulated radiotherapy of prostate cancer based on coverage probabilities.
        Radiother Oncol. 2005; 75: 307-310
        • Beckendorf V.
        • Guerif S.
        • Le Prise E.
        • et al.
        The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity.
        Int J Radiat Oncol Biol Phys. 2004; 60: 1056-1065
        • Bedford J.L.
        • Henrys A.J.
        • Dearnaley D.P.
        • Khoo V.S.
        Treatment planning evaluation of non-coplanar techniques for conformal radiotherapy of the prostate.
        Radiother Oncol. 2005; 75: 287-292
        • Bentzen S.M.
        • Ritter M.A.
        The alpha/beta ratio for prostate cancer: what is it, really?.
        Radiother Oncol. 2005; 76: 1-3
        • Berglund R.k.
        • Sadetsky N.
        • DuChane J.
        • Carroll P.r.
        • Klien E.A.
        Limited pelvic lymph node dissection at the time of radical prostatectomy does not affect 5-year failure rates for low, intermediate and high risk prostate cancer: results from CaPSURE.
        J Urol. 2007; 177: 526-529
        • Boehmer D.
        • Bohsung J.
        • Eichwurzel I.
        • Moys A.
        • Budach V.
        Clinical and physical quality assurance for intensity modulated radiotherapy of prostate cancer.
        Radiother Oncol. 2004; 71: 319-325
        • Boehmer D.
        • Maingon P.
        • Poortmans P.
        • et al.
        Guidelines for primary radiotherapy of patients with prostate cancer.
        Radiother Oncol. 2006; 79: 259-269
        • Bolla M.
        • Collette L.
        • Blank L.
        • et al.
        Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.
        Lancet. 2002; 360: 103-106
        • Bolla M.
        • van Poppel H.
        • Collette L.
        • et al.
        Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911).
        Lancet. 2005; 366: 572-578
        • Bracarda S.
        • de Cobelli O.
        • Greco C.
        • et al.
        Cancer of the prostate.
        Crit Rev Oncol Haematol. 2005; 56: 379-396
        • Brachman D.G.
        • Thomas T.
        • Hilbe J.
        • et al.
        Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice.
        Int J Radiat Oncol Biol Phys. 2000; 48: 111-117
        • Brenner D.J.
        Fractionation and late rectal toxicity.
        Int J Radiat Oncol Biol Phys. 2004; 60: 1013-1015
        • Brenner D.J.
        • Martinez A.A.
        • Edmundson G.K.
        • et al.
        Direct evidence that prostate tumors show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue.
        Int J Radiat Oncol Biol Phys. 2002; 52: 6-13
      2. Brundage M, Lukka H, Crook J, et al. The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 prostate cancer. Cochrane Database Syst Rev, published online 1 Nov. 2005.

        • Buskirk S.J.
        • Pisansky T.M.
        • Atkinson E.J.
        • et al.
        Lymph node-positive prostate cancer: evaluation of the results of the combination of androgen deprivation therapy and radiation therapy.
        Mayo Clin Proc. 2001; 76: 702-706
        • Buskirk S.J.
        • Pisansky T.M.
        • Schild S.E.
        • et al.
        Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system.
        J Urol. 2006; 176: 985-990
        • Carlson D.J.
        • Stewart R.D.
        • Li X.A.
        • Jennings K.
        • Wang J.Z.
        • Guerrero M.
        Comparison of in vitro and in vivo alpha/beta ratios for prostate cancer.
        Phys Med Biol. 2004; 49: 4477-4491
        • Cattani F.
        • Vavassori A.
        • Polo A.
        • et al.
        Radiation exposure after permanent prostate brachytherapy.
        Radiother Oncol. 2006; 79: 65-69
        • Catton C.N.
        • Chung P.
        • Haycocks T.
        • et al.
        Hypofractionated intensity modulated radiation therapy for prostate cancer.
        Int J Radiat Oncol Biol Phys. 2002; 54: 188
        • Cheung R.
        • Kamat A.M.
        • de Crevoisier R.
        • et al.
        Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy.
        Int J Radiat Oncol Biol Phys. 2005; 63: 134-140
        • Cheung R.
        • Tucker L.S.
        • Ye J.S.
        • et al.
        Characterization of rectal normal tissue complication probability after high-dose external beam radiotherapy for prostate cancer.
        Int J Radiat Oncol Biol Phys. 2003; 57: S151
        • Chism D.B.
        • Hanlon A.L.
        • Horwitz E.M.
        • et al.
        A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy.
        Int J Radiat Oncol Biol Phys. 2004; 59: 380-385
        • Choo R.
        • Morton G.
        • Danjoux C.
        • Hong C.
        • Szumacher E.
        • DeBoer G.
        Limited efficacy of salvage radiotherapy for biopsy confirmed or clinically palpable local recurrence of prostate carcinoma after surgery.
        Radiother Oncol. 2005; 74: 163-167
        • Collette L.
        • van Poppel H.
        • Bolla M.
        • et al.
        Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911).
        Eur J Cancer. 2005; 41: 2662-2672
        • Collins C.D.
        • Lloyd-Davies R.W.
        • Swan A.V.
        Radical external beam radiotherapy for localised carcinoma of the prostate using a hypofractionation technique.
        Clin Oncol (R Coll Radiol). 1991; 3: 127-132
        • Collins R.
        • Trowman R.
        • Norman G.
        • et al.
        A systematic review of the effectiveness of docetaxel and mitoxantrone for the treatment of metastatic hormone-refractory prostate cancer.
        Br J Cancer. 2006; 95: 457-462
      3. Consensus statement: the Management of Clinically Localized Prostate Cancer. National Institutes of Health Consensus Development Panel [no authors listed]. NCI Monogr 1988;7:3–6.

        • Cooperberg M.R.
        • Lubeck D.P.
        • Mehta S.S.
        • Carroll P.R.
        Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE).
        J Urol. 2003; 170: S21-S25
        • Corn B.W.
        • Winter K.
        • Pilepich M.V.
        • Radiation Therapy Oncology Group
        Does androgen suppression enhance the efficacy of postoperative irradiation? A secondary analysis of RTOG 85-31.
        Urology. 1999; 54: 495-502
        • Court L.E.
        • D’Amico A.V.
        • Kadam D.
        • Cormack R.
        Motion and shape change when using an endorectal balloon during prostate radiation therapy.
        Radiother Oncol. 2006; 81: 184-189
        • Cox J.
        • Gallagher M.J.
        • Hammond E.H.
        • Kaplan R.S.
        • Schellhammer P.F.
        Consensus statements on radiation therapy of prostate cancer: guidelines for prostate re-biopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy. American Society for Therapeutic Radiology and Oncology Consensus Panel.
        J Clin Oncol. 1999; 17: 1155
        • Crook J.
        • Ludgate C.
        • Malone S.
        • et al.
        Report of a multicenter Canadian phase III trial of 3 months vs 8 months neoadjuvant androgen before standard dose radiotherapy for clinically localized prostate cancer.
        Int J Radiat Oncol Biol Phys. 2004; 60: 15-23
        • Cuzick J.
        • Fisher G.
        • Kattan M.W.
        • Berney D.
        Long-term outcome among men with conservatively treated localised prostate cancer.
        Br J Cancer. 2006; 95: 1186-1194
        • D’Amico A.V.
        • Manola J.
        • Loffredo M.
        • et al.
        6-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.
        JAMA. 2004; 292: 821-827
        • D’Amico A.V.
        • Whittington R.
        • Malkowicz S.B.
        • et al.
        Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
        JAMA. 1998; 280: 969-974
        • de Crevoisier R.
        • Tucker S.L.
        • Dong L.
        • et al.
        Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy.
        Int J Radiat Oncol Biol Phys. 2005; 62: 965-973
        • De Meerleer G.O.
        • Fonteyne V.H.
        • Vakaet L.
        • et al.
        Intensity-modulated radiation therapy for prostate cancer: late morbidity and results on biochemical control.
        Radiother Oncol. 2007; 82: 160-166
        • De Jong I.J.
        • Pruim J.
        • Elsinga P.H.
        • et al.
        Pre-operative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET.
        J Nucl Med. 2003; 44: 331-335
        • Dearnaley D.P.
        • Hall E.
        • Lawrence D.
        • et al.
        Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects.
        B J Cancer. 2005; 92: 488-498
        • Dearnaley D.P.
        • Khoo V.S.
        • Norman A.R.
        • et al.
        Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial.
        Lancet. 1999; 353: 267-272
        • Dearnaley D.P.
        • Sydes M.R.
        • Langley R.E.
        • et al.
        The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: Results from the MRC RT01 trial (ISRCTN47772397).
        Radiother Oncol. 2007; ([Epub ahead of print])
        • Denham J.W.
        • Steigler A.
        • Lamb D.S.
        • et al.
        Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial.
        Lancet Oncol. 2005; 11: 841-850
        • Deore S.M.
        • Shrivastava S.K.
        • Supe S.J.
        • et al.
        Alpha/beta value and importance of dose per fraction for the late rectal and recto-sigmoid complications.
        Strahlenther Onkol. 1993; 26: 244-253
        • Dirix P.
        • Haustermans K.
        • Junius S.
        • Withers R.
        • Oyen R.
        • Van Poppel H.
        The role of whole pelvic radiotherapy in locally advanced prostate cancer.
        Radiother Oncol. 2006; 79: 1-14
        • Donovan J.
        • Mills N.
        • Smith M.
        • et al.
        Quality improvement report: Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. Commentary: presenting unbiased information to patients can be difficult.
        BMJ. 2002; 325: 766-770
        • Dubray B.M.
        • Thames H.D.
        Chronic radiation damage in the rat rectum: an analysis of the influences of fractionation, time and volume.
        Radiother Oncol. 1994; 33: 41-47
        • Duncan W.
        • Warde P.
        • Catton C.N.
        • et al.
        Carcinoma of the prostate: results of radical radiotherapy (1970–1985).
        Int J Radiat Oncol Biol Phys. 1993; 26: 203-210
        • Edelstein R.A.
        • Zietman A.L.
        • de las Morenas A.
        • et al.
        Implications of prostate micrometastases in pelvic lymph nodes: an archival tissue study.
        Urology. 1996; 47: 370-375
        • El-Galley R.E.S.
        • Howard G.C.W.
        • Hawkyard H.S.
        • et al.
        Radical radiotherapy for localized adenocarcinoma of the prostate. A report of 191 cases.
        Br J Urol. 1995; 75: 38-43
        • Ferrari C.A.
        • Stone N.N.
        • Goa M.
        • et al.
        Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high-risk prostate cancer.
        J Natl Cancer Inst. 1997; 89: 1498-1504
        • Fletcher S.G.
        • Mills S.E.
        • Smolkin M.E.
        • Theodorescu D.
        Case-matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer.
        Int J Radiat Oncol Biol Phys. 2006; 66: 1092-1099
        • Fowler F.J.
        • Barry M.J.
        • Lu-Yao G.
        • Wasson J.H.
        • Bin L.
        Outcomes of external beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance epidemiology and end results areas.
        J Clin Oncol. 1996; 14: 2258-2265
        • Fowler J.F.
        • Nahum A.E.
        • Orton C.G.
        Point/Counterpoint. The best radiotherapy for the treatment of prostate cancer involves hypofractionation.
        Med Phys. 2006; 33: 3081-3084
        • Fowler J.F.
        • Ritter M.A.
        • Chappell R.J.
        • Brenner D.J.
        What hypofractionated protocols should be tested for prostate cancer?.
        Int J Radiat Oncol Biol Phys. 2003; 56: 1093-1104
        • Galalae R.M.
        • Kovacs G.
        • Schultze J.
        • et al.
        Long term outcome after elective irradiation on the pelvic lymphatics and local dose escalation using high dose rate brachytherapy for locally advanced prostate cancer.
        Int J Radiat Oncol Biol Phys. 2002; 52: 81-90
        • Geinitz H.
        • Zimmermann F.B.
        • Thamm R.
        • et al.
        Late rectal symptoms and quality of life after conformal radiation therapy for prostate cancer.
        Radiother Oncol. 2006; 79: 341-347
        • Gleave M.
        • Kelly W.K.
        High-risk localized prostate cancer: a case for early chemotherapy.
        J Clin Oncol. 2005; 23: 8186-8191
        • Granfors R.ì.T.
        • Modig H.
        • Damber J.E.
        • Tomic R.
        Long-term followup of a randomized study of locally advanced prostate cancer treated with combined orchiectomy and external radiotherapy versus radiotherapy alone.
        J Urol. 2006; 176: 544-547
        • Greco C.
        • Mazzetta C.
        • Cattani F.
        • et al.
        Finding dose-volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer.
        Radiother Oncol. 2003; 69: 215-222
        • Guedea F.
        • Aguilo F.
        • Polo A.
        • et al.
        Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1–T2 prostate cancer.
        Radiother Oncol. 2006; 80: 57-61
      4. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol 2003;21:3972–8.

        • Harisinghani M.G.
        • Barentsz J.O.
        • Hahn P.R.
        • et al.
        Non-invasive detection of clinically occult lymph node metastasis in prostate cancer.
        N Engl J Med. 2003; 348: 2491-2499
        • Hayes S.B.
        • Pollack A.E.
        Parameters for treatment decisions for salvage radiation therapy.
        J Clin Oncol. 2005; 23: 8204-8211
        • Herold D.M.
        • Hanlon A.L.
        • Hanks G.E.
        Diabetes mellitus: a predictor for late radiation morbidity.
        Int J Radiat Oncol Biol Phys. 1999; 43: 475-479
        • Herstein A.
        • Wallner K.
        • Merrick G.
        • et al.
        I-125 versus Pd-103 for low-risk prostate cancer: long-term morbidity outcomes from a prospective randomized multicenter controlled trial.
        Cancer J. 2005; 11: 385-389
        • Higgins G.S.
        • McLaren D.B.
        • Kerr G.R.
        • Elliott T.
        • Howard G.C.W.
        Outcome analysis of 300 prostate cancer patients treated with neoadjuvant androgen deprivation and hypofractionated radiotherapy.
        Int J Radiat Oncol Biol Phys. 2006; 65: 982-989
        • Hong T.S.
        • Tome W.A.
        • Jaradat H.
        • Raisbeck B.M.
        • Ritter M.A.
        Pelvic nodal dose escalation with prostate hypofractionation using conformal avoidance defined (H-CAD) intensity modulated radiation therapy.
        Acta Oncol. 2006; 45: 717-727
        • Isaka S.
        • Shimazaki J.
        • Akimoto S.
        • et al.
        A prospective randomized trial for treating stages B2 and C prostate cancer: radical surgery or irradiation with neoadjuvant endocrine therapy.
        Jpn J Clin Oncol. 1994; 24: 218-223
        • Ishikawa H.
        • Tsuji H.
        • Kamada T.
        • et al.
        Carbon ion radiation therapy for prostate cancer: results of a prospective phase II study.
        Radiother Oncol. 2006; 81: 57-64
        • Iversen P.
        • Johansson J.E.
        • Lodding P.
        • et al.
        Bicalutamide 150 mg in addition to standard care for patients with early non-metastatic prostate cancer Updated results from the Scandinavian Prostate Cancer Period Group-6 Study after a median follow-up period of 7.1 years.
        Scand J Urol Nephrol. 2006; 40: 441-452
        • Izard M.A.
        • Haddad R.L.
        • Fogarty G.B.
        • Rinks A.
        • Dobbins T.
        • Katelaris P.
        Six year experience of external beam radiotherapy, brachytherapy boost with a 1Ci (192)Ir source, and neoadjuvant hormonal manipulation for prostate cancer.
        Int J Radiat Oncol Biol Phys. 2006; 66: 38-47
        • Jacob R.
        • Hanlon A.L.
        • Horwitz E.M.
        • et al.
        The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer.
        Cancer. 2004; 100: 538-543
        • Jani A.B.
        • Gratzle J.
        Late radiotherapy toxicity after prostate cancer treatment: influence of hormonal therapy.
        Urology. 2005; 66: 566-570
        • Jani A.B.
        • Gratzle J.
        • Correa D.
        Influence of intensity-modulated radiotherapy on acute genitourinary and gastrointestinal toxicity in the treatment of localized prostate cancer.
        Technol Cancer Res Treat. 2007; 6: 11-15
        • Jani A.B.
        • Su A.
        • Correa D.
        • Gratzle J.
        Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields.
        Prostate Cancer Prostatic Dis. 2007; 10: 82-86
        • Jemal A.
        • Siegel R.
        • Ward E.
        • et al.
        Cancer statistics, 2006.
        Cancer J Clin. 2006; 56: 106-130
        • Jereczek-Fossa B.A.
        • Cattani F.
        • D’Onofrio A.
        • et al.
        Dose distribution in 3-dimensional conformal radiotherapy for prostate cancer: Comparison of two treatment techniques (six coplanar fields and two dynamic arcs).
        Radiother Oncol. 2006; 81: 294-302
        • Kaplan I.D.
        • Meskell P.M.
        • Lieberfarb M.
        • Saltzman B.
        • Berg S.
        • Holupka E.J.
        A comparison of the precision of seeds deposited as loose seeds versus suture embedded seeds: a randomized trial.
        Brachytherapy. 2004; 3: 7-9
        • Karlsdottir A.
        • Johannessen D.C.
        • Muren L.P.
        • Wenzel-Larsen T.
        • Dahl O.
        Acute morbidity related to treatment volume during 3D-conformal radiation therapy for prostate cancer.
        Radiother Oncol. 2004; 71: 43-53
        • Kestin L.L.
        • Vicini F.A.
        • Martinez A.A.
        Practical application of biochemical failure definitions: what to do and when to do it.
        Int J Radiat Oncol Biol Phys. 2002; 53: 304-315
        • Kitamura K.
        • Shirato H.
        • Shinohara N.
        • et al.
        Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time tumor-tracking system for prostate cancer: preliminary results of a phase I/II study.
        Cancer J. 2003; 9: 268-276
        • Klotz L.
        Active surveillance for prostate cancer: for whom?.
        J Clin Oncol. 2005; 32: 8165-8169
        • Koper P.C.
        • Jansen P.
        • van Putten W.
        • et al.
        Gastro-intestinal and genito-urinary morbidity after 3D conformal radiotherapy of prostate cancer: observations of a randomized trial.
        Radiother Oncol. 2004; 73: 1-9
        • Koper P.C.
        • Stroom J.C.
        • van Putten W.L.
        • et al.
        Acute morbidity reduction using 3DCRT for prostate carcinoma: a randomized study.
        Int J Radiat Oncol Biol Phys. 1999; 43: 727-734
        • Koukourakis M.I.
        • Touloupidis S.
        External beam radiotherapy for prostate cancer: current position and trends.
        Anticancer Res. 2006; 26: 485-494
        • Kovacs G.
        • Potter R.
        • Loch T.
        • et al.
        GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer.
        Radiother Oncol. 2005; 74: 137-148
        • Kuban D.A.
        • Poyyers L.
        • Lawton C.A.
        • Pisansky T.M.
        Prostate cancer.
        in: Gunderson L.L. Tepper J.E. Clinical radiation oncology. 2nd ed. Churchill Livingstone, Philadelphia2007: 1165-1236
        • Kucway R.
        • Vicini F.
        • Huang R.
        • et al.
        Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy.
        J Urol. 2002; 167: 2443-2447
        • Kumar S.
        • Shelley M.
        • Harrison C.
        • Coles B.
        • Wilt T.J.
        • Mason M.D.
        Neo-adjuvant and adjuvant hormone therapy for localized and locally advanced prostate cancer.
        Cochrane Database Syst Rev. 2006; 4: CD006019
        • Kupelian P.A.
        • Buchsbaum J.C.
        • Eishaikh M.A.
        • Reddy C.A.
        • Klein E.A.
        Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.
        Int J Radiat Oncol Biol Phys. 2003; 57: 629-634
        • Kupelian P.A.
        • Elshaikh M.
        • Reddy C.
        • Zippe C.
        • Klein E.A.
        Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: A large single-institution experience with radical prostatectomy and external beam radiotherapy.
        J Clin Oncol. 2002; 20: 3376-3385
        • Kupelian P.A.
        • Katcher J.
        • Levin H.S.
        • Klein E.A.
        Staging T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
        Int J Radiat Oncol Biol Phys. 1997; 37: 1043-1052
        • Kupelian P.A.
        • Potters L.
        • Khuntia D.
        • et al.
        Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1–T2 prostate cancer.
        Int J Radiat Oncol Biol Phys. 2004; 58: 25-33
        • Kupelian P.A.
        • Thakkar V.V.
        • Khuntia D.
        • Reddy C.A.
        • Klein E.A.
        • Mahadevan A.
        Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Long term results.
        Int J Radiat Oncol Biol Phys. 2005; 63: 1438-1463
        • Lavardiere J.
        • Gomez J.L.
        • Cusan L.
        • et al.
        Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer.
        Int J Radiat Oncol Biol Phys. 1997; 7: 247-252
        • Laverdiere J.
        • Nabid A.
        • De Bedoya L.D.
        • et al.
        The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2–T3 prostate cancer.
        J Urol. 2004; 171: 1137-1140
        • Lee A.K.
        Radiation therapy combined with hormone therapy for prostate cancer.
        Semin Radiat Oncol. 2006; 16: 20-22
        • Lee A.K.
        • D’Amico A.V.
        Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy.
        J Clin Oncol. 2005; 23: 8192-8197
        • Lee C.T.
        • Dong L.
        • Ahmad A.W.
        • et al.
        Comparison of treatment volumes and techniques in prostate cancer radiation therapy.
        Am J Clin Oncol. 2005; 28: 618-625
        • Lee N.
        • Newhouse J.H.
        • Olsson C.A.
        • et al.
        Which patients with newly diagnosed prostate cancer need a CT scan of the abdomen and pelvis? An analysis of 588 patients.
        Urology. 1999; 54: 490-494
        • Leibel S.A.
        • Fuks Z.
        • Zelefsky M.J.
        • Whitmore Jr, W.F.
        The effects of local and regional treatments on the metastatic outcome in prostatic carcinoma with pelvic lymph node involvement.
        Int J Radiat Oncol Biol Phys. 1994; 28: 7-16
        • Lennemas B.
        • Egdren M.
        • Haggman M.
        • Norlen B.J.
        • Nilsson S.
        Postoperative radiotherapy after prostatectomy – a review.
        Scand J Urol Nephrol. 2003; 37: 10-15
        • Letourneau D.
        • Wong J.W.
        • Oldham M.
        • et al.
        Cone-beam-CT guided radiation therapy: technical implementation.
        Radiother Oncol. 2005; 75: 279-286
        • Levegrun S.
        • Jackson A.
        • Zelefsky M.J.
        • et al.
        Risk group dependence of dose–response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer.
        Radiother Oncol. 2002; 63: 11-26
        • Liu M.
        • Pickles T.
        • Berthelet E.
        • et al.
        Urinary incontinence in prostate cancer patients treated with external beam radiotherapy.
        Radiother Oncol. 2005; 74: 197-201
        • Livsey J.E.
        • Cowan R.A.
        • Wylie J.P.
        • et al.
        Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis.
        Int J Radiat Oncol Biol Phys. 2003; 57: 1254-1259
        • Loblaw D.A.
        • Cheung P.
        External beam irradiation for localized prostate cancer – the promise of hypofractionation.
        Can J Urol. 2006; 13: 62-66
        • Lotan Y.
        • Stanfiled J.
        • Cho L.C.
        • et al.
        Efficacy of high dose per fraction radiation for implanted human prostate cancer in a nude mouse model.
        J Urol. 2006; 175: 1932-1936
        • Lukka H.
        • Hayter C.
        • Julian J.A.
        • et al.
        Randomized trial comparing two fractionation schedules for patients with localized prostate cancer.
        J Clin Oncol. 2005; 23: 6132-6138
        • Lukka H.
        • Pickles T.
        • Morton G.
        • et al.
        Prostate cancer radiotherapy 2002: the way forward.
        Can J Urol. 2005; 12: 2521-2531
        • Luxton G.
        • Hancock S.L.
        • Boyer A.L.
        Dosimetry and radiobiologic model comparison of IMRT and 3D conformal radiotherapy in treatment of carcinoma of the prostate.
        Int J Radiat Oncol Biol Phys. 2004; 59: 267-284
        • Madsen B.L.
        • Hsi R.A.
        • Pham H.T.
        • Fowler J.F.
        • Esagui L.
        • Corman J.
        Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results.
        Int J Radiat Oncol Biol Phys. 2007; 67: 1099-1105
        • Mangar S.A.
        • Sydes M.R.
        • Tucker H.L.
        • et al.
        Evaluating the relationship between erectile dysfunction and dose received by the penile bulb: using data from a randomised controlled trial of conformal radiotherapy in prostate cancer (MRC RT01, ISRCTN47772397).
        Radiother Oncol. 2006; 80: 355-362
        • Martinez A.A.
        • Demanes D.J.
        • Galalae R.
        • et al.
        Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
        Int J Radiat Oncol Biol Phys. 2005; 62: 1322-1331
        • Merrick G.S.
        • Buttler W.M.
        • Wallner K.E.
        • et al.
        The importance of radiation doses to the penile bulb vs. crura in the development of postbrachytherapy erectile dysfunction.
        Int J Radiat Oncol Biol Phys. 2002; 54: 1055-1062
        • McGowan D.G.
        The value of extended field radiation therapy in carcinoma of the prostate.
        Int J Radiat Oncol Biol Phys. 1981; 7: 1333-1339
        • McLoad D.G.
        • See W.A.
        • Klimberg I.
        • et al.
        The bicalutamide 150 mg early prostate cancer program: findings of the North American trial at 7.7-year median follow-up.
        J Urol. 2006; 176: 75-80
        • Mills N.
        • Donovan J.
        • Smith M.
        • Jacoby A.
        • Neal D.
        • Hamdy F.C.
        Perceptions of equipoise are crucial to trial participation: a qualitative study of men in the ProtecT study.
        Control Clin Trials. 2003; 24: 272-282
        • Mills N.
        • Metcalfe C.
        • Ronsmans C.
        • et al.
        A comparison of socio-demographic and psychological factors between patients consenting to randomisation and those selecting treatment (the ProtecT study).
        Contemp Clin Trials. 2006; 27: 413-419
        • Mock U.
        • Mayer R.
        • Potter R.
        • et al.
        The med AUSTRON/OGRO patterns of care study on radiotherapy indications in Austria.
        Radiother Oncol. 2004; 73: S29-S34
        • Mohan D.S.
        • Kupelian P.A.
        • Willoughby T.R.
        Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland.
        Int J Radiat Oncol Biol Phys. 2000; 46: 575-580
        • Morris D.
        • Emami B.
        • Mauch P.M.
        • et al.
        Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative.
        Int J Radiat Oncol Biol Phys. 2005; 62: 3-19
        • Mott J.H.
        • Livsey J.E.
        • Logue J.P.
        Development of a simultaneous boost IMRT class solution for a hypofractionated prostate cancer protocol.
        Br J Radiol. 2004; 77: 377-386
        • Nahum A.E.
        • Chapman J.
        In response: Incorporating clinical measurements of hypoxia into local tumor control modelling of prostate cancer.
        Int J Radiat Oncol Biol Phys. 2004; 58: 1637-1639
        • Nahum A.E.
        • Movsas B.
        • Horwitz E.M.
        • Stobbe C.C.
        • Chapman J.D.
        Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio.
        Int J Radiat Oncol Biol Phys. 2003; 57: 391-401
        • Narayana V.
        • Troyer S.
        • Evans V.
        • et al.
        Randomized trial of high- and low-source strength (125)I prostate seed implants.
        Int J Radiat Oncol Biol Phys. 2005; 61: 44-51
        • Nguyen K.H.
        • Horwitz E.M.
        • Hanlon A.L.
        • et al.
        Does short-term androgen deprivation substitute for radiation dose in the treatment of high-risk prostate cancer?.
        Int J Radiat Oncol Biol Phys. 2003; 57: 377-383
        • Nichol A.M.
        • Warde P.
        • Bristow R.G.
        Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy.
        Cancer. 2005; 104: 891-905
        • Nickers P.
        • Coppens L.
        • de Leval J.
        • Jansen N.
        • Debneufbourg J.M.
        192Ir low dose rate brachytherapy for boosting locally advanced prostate cancers after external beam radiotherapy: a phase II trial.
        Radiother Oncol. 2006; 79: 329-334
        • Nilsson S.
        • Norlen B.J.
        • Widmark A.
        A systematic overview of radiation therapy effects in prostate cancer.
        Acta Oncol. 2004; 43: 316-381
        • Nutting C.M.
        • Convery D.J.
        • Cosgrove V.P.
        • et al.
        Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer.
        Int J Radiat Oncol Biol Phys. 2000; 48: 649-656
        • O’Daniel J.C.
        • Dong L.
        • Zhang L.
        • et al.
        Dosimetric comparison of four target alignment methods for prostate cancer radiotherapy.
        Int J Radiat Oncol Biol Phys. 2006; 66: 883-891
        • Okegawa T.
        • Nutahara K.
        • Higashihara E.
        Detection of micrometastatic prostate cancer cells in the lymph nodes by reverse transcriptase polymerase chain reaction is predictive of biochemical recurrence in pathological stage T2 prostate cancer.
        J Urol. 2000; 163: 1183-1188
      5. Orton C. In regard to Nahum et al. (Int J Radiat Oncol Biol Phys 2003;57:391–401): Incorporating clinical measurements of hypoxia into tumor control modeling of prostate cancer: implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys. 2004;58:1637.

        • Pan C.C.
        • Kim K.Y.
        • Taylor J.M.
        • et al.
        Influence of 3D-CRT pelvic irradiation on outcome in prostate cancer treated with external beam radiotherapy.
        Int J Radiat Oncol Biol Phys. 2002; 53: 1139-1145
        • Parker C.
        Active surveillance: towards a new paradigm in the management of early prostate cancer.
        Lancet Oncol. 2004; 5: 101-106
        • Parker C.
        • Warde P.
        • Catton C.
        Salvage radiotherapy for PSA failure after radical prostatectomy.
        Radiother Oncol. 2001; 61: 107-116
        • Partin A.W.
        • Kattan M.W.
        • Subong E.N.
        • et al.
        Combination of prostate -specific antigen, clinical stage and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.
        JAMA. 1997; 227: 1445-1451
        • Partin A.W.
        • Mangold L.A.
        • Lamm D.A.
        • et al.
        Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium.
        Urology. 2001; 58: 843-848
        • Partin A.W.
        • Yoo J.
        • Carter B.
        • et al.
        The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localised prostate cancer.
        J Urol. 1993; 150: 110-114
        • Patel A.R.
        • Sandler H.M.
        • Pienta K.J.
        Radiation Therapy Oncology Group 0521: a phase III randomized trial of androgen suppression and radiation therapy versus androgen suppression and radiation therapy followed by chemotherapy with docetaxel/prednisone for localized, high-risk prostate cancer.
        Clin Genitourin Cancer. 2005; 4: 212-214
        • Paulson D.F.
        • Lin G.H.
        • Hinshaw L.
        • et al.
        Radical surgery versus radiotherapy for adenocarcinoma of the prostate.
        J Urol. 1982; 128: 502-504
        • Peeters S.T.H.
        • Heemsbergen W.D.
        • Koper P.C.M.
        • et al.
        Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy.
        J Clin Oncol. 2006; 24: 1990-1996
        • Peignaux K.
        • Truc G.
        • Barillot I.
        • et al.
        Clinical assessment of the use of the Sonarray system for daily prostate localization.
        Radiother Oncol. 2006; 81: 176-178
        • Pickett B.
        • Kurhanewicz J.
        • Pouliot J.
        • et al.
        Three-dimensional conformal external beam radiotherapy compared with permanent prostate implantation in low-risk prostate cancer based on endorectal magnetic resonance spectroscopy imaging and prostate-specific antigen level.
        Int J Radiat Oncol Biol Phys. 2006; 65: 65-72
        • Pilepich M.V.
        • Krall J.M.
        • Johnson R.J.
        • et al.
        Extended field (peri-aortic) irradiation in carcinoma of the prostate-analysis of RTOG 75-06.
        Int J Radiat Oncol Biol Phys. 1986; 12: 345-351
        • Pilepich M.V.
        • Winter K.
        • John M.J.
        • et al.
        Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
        Int J Radiat Oncol Biol Phys. 2001; 50: 1243-1252
        • Pilepich M.V.
        • Winter K.
        • Lawton C.A.
        • et al.
        Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma: Long-term results of phase III RTOG 85-31.
        Int J Radiat Oncol Biol Phys. 2005; 61: 1285-1290
        • Pisansky T.M.
        External-beam radiotherapy for localized prostate cancer.
        N Engl J Med. 2006; 355: 1583-1591
        • Ploysongsang S.S.
        • Aron B.S.
        • Shehata W.M.
        Radiation therapy in prostate cancer: whole pelvis with prostate boost or small field to prostate?.
        Urology. 1991; : 4018-4026
        • Pollack A.
        • Hanlon A.L.
        • Horwitz E.M.
        • et al.
        Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial.
        Int J Radiat Oncol Biol Phys. 2006; 64: 518-526
        • Pollack A.
        • Zagars G.K.
        • Smith L.G.
        • et al.
        Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer.
        J Clin Oncol. 2000; 18: 3904-3911
        • Pollack A.
        • Zagars G.K.
        • Starkschall G.
        • et al.
        Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial.
        Int J Radiat Oncol Biol Phys. 2002; 53: 1097-1105
        • Potters L.
        • Torre T.
        • Ashley R.
        • Leibel S.
        Examining the role of neoadjuvant androgen deprivation in patients undergoing prostate brachytherapy.
        J Clin Oncol. 2000; 18: 1187-1192
      6. PR06 Collaborators. Early closure of a randomized controlled trial of three treatment approaches to early localised prostate cancer: the MRC PR06 trial. BJU Int 2004;94:1400–1.

      7. Prostate cancer. In: National Comprehensive Cancer network Clinical Practice Guidelines in Oncology, version 1.2007. Jenkinstown, PA: National Comprehensive Cancer Network, March 2007. Available from: http://www.nccn.org/professionals/physician_gls/default.asp.

      8. Prostate nomograms. New York: Memorial Sloan-Kettering Cancer Center; 2006. Available from: http://www.nomograms.org.

        • Rancati T.
        • Fiorino C.
        • Gagliardi G.
        • et al.
        Fitting late rectal bleeding data using different NTCP models: Results from an Italian multi-centric study (AIROPROS0101).
        Radiother Oncol. 2004; 73: 21-32
        • Rasp G.M.
        • Pisansky T.M.
        • Haddock M.G.
        • et al.
        Elective pelvic nodal irradiation in patients with clinically localized prostate cancer at high risk for pelvic nodal involvement.
        Int J Radiat Oncol Biol Phys. 1996; 36: S245
        • Read G.
        • Pointon R.C.
        Retrospective study of radiotherapy in early carcinoma of the prostate.
        Br J Urol. 1989; 63: 191-195
        • Roach M III, M.
        • DeSilvio M.
        • Lawton C.
        • et al.
        A phase III trial comparing whole pelvic versus prostate only radiotherapy and neoadjuvant concurrent versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group (RTOG) 9413.
        J Clin Oncol. 2003; 21: 1904-1911
        • Roach III, M.
        • DeSilvio M.
        • Thomas C.R.
        • et al.
        Whole-pelvis, “mini-pelvis,” or prostate-only external beam radiotherapy after neoadjuvant and concurrent hormonal therapy in patients treated in the Radiation Therapy Oncology Group 9413 trial.
        Int J Radiat Oncol Biol Phys. 2006; 66: 647-653
        • Roach III, M.
        • Hanks G.
        • Thames jr., T.
        Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.
        Int J Radiat Oncol Biol Phys. 2006; 65: 965-974
        • Roach III, M.
        • Lu J.
        • Pilepich M.V.
        • et al.
        Predicting long term-survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials.
        Int J Radiat Oncol Biol Phys. 2000; 47: 617-627
        • Roach jr., M.
        • Marquez C.
        • Yuo H.
        • et al.
        Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer.
        Int J Radiat Oncol Biol Phys. 1993; 28: 33-37
        • Roach jr., M.
        • Shinohara K.
        • Weinberg V.
        • et al.
        Contemporary results of permanent prostate seed implantation (PPI) versus conformal proton beam radiotherapy (CPBRT) to 79GyE.
        J Clin Oncol. 2005; 23 (abstr 4639): 412s
        • Roach M.
        • Winter K.
        • Michalski J.M.
        • et al.
        Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study.
        Int J Radiat Oncol Biol Phys. 2004; 60: 1351-1356
        • Robinson J.W.
        • Moritz S.
        • Fung T.
        Meta-analysis of rates of erectile function after treatment of localized prostate carcinoma.
        Int J Radiat Oncol Biol Phys. 2002; 54: 1063-1068
        • Rodrigues G.
        • Yartsev S.
        • Chen J.
        • et al.
        A comparison of prostate IMRT and helical tomotherapy class solutions.
        Radiother Oncol. 2006; 80: 374-377
        • Roscigno M.
        • Cozzarini C.
        • Scattoni C.
        • et al.
        A reappraisal of the role of vesicourethral anastomosis biopsy in patient candidates for salvage radiation therapy after radical prostatectomy.
        Radiother Oncol. 2007; 82: 30-37
        • Rosen E.
        • Cassady J.R.
        • Connolly J.
        • et al.
        Radiotherapy for prostate carcinoma: the JCRT experience (1968–1978). II. Factors related to tumour control and complications.
        Int J Radiat Oncol Biol Phys. 1985; 11: 725-730
        • Salembier C.
        • Lavagnini P.
        • Nickers P.
        • et al.
        Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy.
        Radiother Oncol. 2007; ([Epub ahead of print])
        • Sands M.E.
        • Pollack A.
        • Zagars G.K.
        Influence of radiotherapy on node-positive prostate cancer treated with androgen ablation.
        Int J Radiat Oncol Biol Phys. 1995; 31: 13-19
        • Sanguineti G.
        • Agostinelli S.
        • Foppiano F.
        • et al.
        Adjuvant androgen deprivation impacts late rectal toxicity after conformal radiotherapy of prostate carcinoma.
        Br J Cancer. 2002; 86: 1843-1847
        • Sanguineti G.
        • Cavey M.L.
        • Endres E.J.
        • et al.
        Is IMRT needed to spare the rectum when pelvic lymph nodes are part of the initial treatment volume for prostate cancer?.
        Int J Radiat Oncol Biol Phys. 2006; 64: 151-160
        • Sanguineti G.
        • Marcenaro M.
        • Franzone P.
        • et al.
        Neoadjuvant androgen deprivation and prostate gland shrinkage during conformal radiotherapy.
        Radiother Oncol. 2003; 66: 151-157
        • Saper P.M.
        • Lopez Carrizosa M.C.
        • Perez Casas A.
        • et al.
        Impact of neoadjuvant hormonal therapy on dose-volume histograms in patients with localized prostate cancer under radical radiation therapy.
        Clin Transl Oncol. 2006; 8: 599-605
        • Sathya J.R.
        • Davis I.R.
        • Julian J.A.
        • et al.
        Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate.
        J Clin Oncol. 2005; 23: 1192-1199
        • Schulz-Ertner D.
        • Jakel O.
        • Schlegel W.
        Radiation therapy with charged particles.
        Semin Radiat Oncol. 2006; 16: 249-259
        • Seaward S.A.
        • Weinberg V.
        • Lewis P.
        • et al.
        Identification of a high-risk clinically localised prostate cancer subgroup receiving maximum benefit from whole-pelvic irradiation.
        Cancer J Sci Am. 1998; 4: 370-377
        • Seaward S.A.
        • Weinberg V.
        • Lewis P.
        • et al.
        Improved freedom from PSA failure with whole pelvic irradiation for high-risk prostate cancer.
        Int J Radiat Oncol Biol Phys. 1998; 42: 1055-1062
        • See W.A.
        • Tyrrell C.J.
        • Casodextrade mark Early Prostate Cancer Trialists’ Group
        The addition of bicalutamide 150 mg to radiotherapy significantly improves overall survival in men with locally advanced prostate cancer.
        J Cancer Res Clin Oncol. 2006; 132: 7-13
        • Selek U.
        • Cheung R.
        • Lii M.
        • et al.
        Erectile dysfunction and radiation dose to penile base structures: a lack of correlation.
        Int J Radiat Oncol Biol Phys. 2004; 59: 1039-1046
        • Shariat S.F.
        • Kattan M.W.
        • Erdamar S.
        • et al.
        Detection of clinically significant, occult prostate cancer metastases in lymph nodes using a splice variant-specific rt-PCR assay for human glandular kallikrein.
        J Clin Oncol. 2003; 21: 1223-1231
        • Shipley W.U.
        • Verhey L.J.
        • Munzenrider J.E.
        • et al.
        Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone.
        Int J Radiat Oncol Biol Phys. 1995; 32: 3-12
        • Shu H.K.
        • Lee T.T.
        • Vigneauly E.
        • et al.
        Toxicity following high-dose three dimensional conformal and intensity-modulated radiation therapy for clinically localized prostate cancer.
        Urology. 2001; 57: 102-107
        • Shultheiss T.E.
        • Lee W.R.
        • Hunt M.A.
        • Hanlon A.L.
        • Peter R.S.
        • Hanks G.E.
        Late GI and GU complications in the treatment of prostate cancer.
        Int J Radiat Oncol Biol Phys. 1997; 37: 3-11
        • Simmons M.N.
        • Stephenson A.J.
        • Klien E.A.
        Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy.
        Eur Urol. 2007; ([Epub ahead of print])
        • Sobin L.H.
        • Witteking C.
        TNM. Classification of malignant tumors. UICC.
        6th ed. Wiley-Liss, New York2002
        • Soete G.
        • Arcangeli S.
        • De Meerleer G.
        • et al.
        Phase II study of a four-week hypofractionated external beam radiotherapy regimen for prostate cancer: report on acute toxicity.
        Radiother Oncol. 2006; 80: 78-91
        • Soete G.
        • Verellen D.
        • Tournel K.
        • Storme G.
        Setup accuracy of stereoscopic X-ray positioning with automated correction for rotational errors in patients treated with conformal arc radiotherapy for prostate cancer.
        Radiother Oncol. 2006; 80: 371-373
        • Song W.Y.
        • Schaly B.
        • Bauman G.
        • Battista J.J.
        • Van Dyk J.
        Evaluation of image-guided radiation therapy (IGRT) technologies and their impact on the outcomes of hypofractionated prostate cancer treatments: a radiobiologic analysis.
        Int J Radiat Oncol Biol Phys. 2006; 64: 289-300
        • Speight J.L.
        • Roach III, M.
        Advances in the treatment of localized prostate cancer: the role of anatomic and functional imaging in men managed with radiotherapy.
        J Clin Oncol. 2007; 25: 987-995
        • Speight J.L.
        • Roach III, M.
        Radiotherapy in the management of clinically localized prostate cancer: evolving standards, consensus, controversies and new directions.
        J Clin Oncol. 2005; 23: 8176-8185
        • Stephenson A.J.
        • Shariat S.F.
        • Zelefsky M.J.
        • et al.
        Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
        JAMA. 2004; 291: 1325-1332
        • Stephenson A.J.
        • Slawin K.M.
        The value of radiotherapy in treating recurrent prostate cancer after radical prostatectomy.
        Nat Clin Pract Urol. 2004; 1: 90-96
        • Stock R.G.
        • Ho A.
        • Cesaretti J.A.
        • Stone N.N.
        Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control.
        Int J Radiat Oncol Biol Phys. 2006; 66: 389-394
        • Swanson G.P.
        • Faulkner J.
        • Smalley S.R.
        • et al.
        Locally advanced prostate cancer treated with concomitant radiation and 5-fluorouracil: Southwest Oncology Group Study 9024.
        J Urol. 2006; 176: 548-553
        • Swanson G.P.
        • Thompson I.M.
        • Basler J.
        Treatment options in lymph node-positive prostate cancer.
        Cancer. 2006; 106: 2531-2539
        • Swindle P.
        • Eastham J.A.
        • Ohori M.
        • et al.
        Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens.
        J Urol. 2005; 174: 903-907
        • Sydes M.R.
        • Stephens R.J.
        • Moore A.R.
        • et al.
        Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer.
        Radiother Oncol. 2004; 72: 199-211
        • Tang J.I.
        • Williams S.G.
        • Tai K.H.
        • Dean J.
        • Duchesne G.M.
        A prospective dose escalation trial of high-dose-rate brachytherapy boost for prostate cancer: evidence of hypofractionation efficacy?.
        Brachytherapy. 2006; 5: 256-261
        • Tetzalaff B.S.
        • Timme T.L.
        • et al.
        Expanding the therapeutic index of radiation therapy by combining in situ gene therapy in the treatment of prostate cancer.
        Technol Cancer Res Treat. 2006; 5 (The): 23-36
        • Thames H.D.
        • Kuban D.A.
        • DeSilvio M.L.
        • et al.
        Increasing external beam dose for T1–T2 prostate cancer: effect on risk groups.
        Int J Radiat Oncol Biol Phys. 2006; 65: 975-981
        • Thompson Jr., I.M.
        • Tangen C.M.
        • Paradelo J.
        • et al.
        Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial.
        JAMA. 2006; 296: 2329-2335
        • Tobler M.
        • Watson G.
        • Laevitt D.D.
        The application of dynamic filed shaping and dynamic dose rate control in conformal rotational treatment of the prostate.
        Med Dosim. 2002; 27: 251-254
        • Tward J.D.
        • Lee C.M.
        • Pappas L.M.
        • et al.
        Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis.
        Cancer. 2006; 107: 2392-2400
        • Tyrrel C.J.
        • Payne H.
        • See W.A.
        • et al.
        Bicalutamide (‘Casodex’) 150 mg as adjuvant to radiotherapy in patients with localised or locally advanced prostate cancer: results from the randomised Early Prostate Cancer Programme.
        Radiother Oncol. 2005; 76: 4-10
        • Valdagni R.
        • Italia C.
        • Montanaro P.
        • et al.
        Is the alpha-beta ratio of prostate cancer really low? A prospective, non-randomized trial comparing standard and hyperfractionated conformal radiation therapy.
        Radiother Oncol. 2005; 75: 74-82
        • van den Heuvel F.
        • Fugazzi J.
        • Seppi E.
        • Forman J.D.
        Clinical application of a repositioning scheme, using gold markers and electronic portal imaging.
        Radiother Oncol. 2006; 79: 94-100
        • van der Heide U.A.
        • Kotte A.N.
        • Dehnad H.
        • Hofman P.
        • Lagenijk J.J.
        • van Vulpen M.
        Analysis of fiducial marker-based position verification in the external beam radiotherapy of patients with prostate cancer.
        Radiother Oncol. 2007; 82: 38-45
        • van Lin E.N.
        • Futterer J.J.
        • Heijmink S.W.
        • et al.
        IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI.
        Int J Radiat Oncol Biol Phys. 2006; 65: 291-303
        • van Tol-Geerdink J.J.
        • Stalmeier P.F.
        • Pasker-de Jong P.C.
        • et al.
        Systematic review of the effect of radiation dose on tumor control and morbidity in the treatment of prostate cancer by 3D-CRT.
        Int J Radiat Oncol Biol Phys. 2006; 64: 5343-5345
        • Vargas C.E.
        • Galalae R.
        • Boike T.P.
        • et al.
        Matched-pair analysis of prostate cancer patients with a high risk of positive pelvic lymph nodes treated with and without pelvic RT and high-dose radiation using high dose rate brachytherapy.
        Am J Clin Oncol. 2006; 29: 45145-45147
        • Vavassori V.
        • Fiorino C.
        • Rancati T.
        • et al.
        Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study.
        Int J Radiat Oncol Biol Phys. 2007; ([Epub ahead of print])
        • Vulto A.
        • Louwman M.
        • Rodrigus P.
        • Coebergh J.W.
        Referral rates and trends in radiotherapy as part of primary treatment of cancer in South Netherlands,1988–2002.
        Radiother Oncol. 2006; 78: 131-137
        • Wallace K.
        • Fleshner N.
        • Basiuk J.
        • Crook J.
        Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the Surgical Prostatectomy Versus Interstitial radiation Intervention Trial.
        J Clin Oncol. 2006; 24: 4158-4162
        • Wallner K.
        • Merrick G.
        • True L.
        • Sutlief S.
        • Cavanagh W.
        • Butler W.
        125-I versus 103-Pd for low-risk prostate cancer: Preliminary PSA outcomes from a prospective randomized multicenter trial.
        Int J Radiat Oncol Biol Phys. 2003; 57: 1297-1303
        • Wallner K.
        • Merrick G.
        • True L.
        • et al.
        20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial.
        Radiother Oncol. 2005; 75: 307-310
        • Wang J.Z.
        • Guerrero M.
        • Li X.A.
        How low is the α/β ratio for prostate cancer?.
        Int J Radiat Oncol Biol Phys. 2003; 55: 194-203
        • Weckermann D.
        • Dorn R.
        • Trefz M.
        • Anger T.
        • Wawroschek F.
        • Harzmann R.
        Sentinel lymph node dissection for prostate cancer: experience with more than 1,000 patients.
        J Urol. 2007; 177: 916-920
        • Weckermann D.
        • Goppelt M.
        • Dorn R.
        • Wawroschek F.
        • Harzmann R.
        Incidence of positive pelvic lymph nodes in patients with prostate cancer, a prostate-specific antigen (PSA) level of < or =10 ng/mL and biopsy Gleason score of < or =6, and their influence on PSA progression-free survival after radical prostatectomy.
        BJU Int. 2006; 97: 1173-1178
        • Whittington R.
        • Malkowicz B.
        • Machtay M.
        • et al.
        The use of combined radiation therapy and hormonal therapy in the management of lymph node-positive prostate cancer.
        Int J Radiat Oncol Biol Phys. 1997; 39: 673-680
        • Xia P.
        • Pickett B.
        • Vigneault E.
        • et al.
        Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy.
        Int J Radiat Oncol Biol Phys. 2001; 51: 244-254
        • Xing L.
        • Thorndyke B.
        • Schreibmann E.
        • et al.
        Overview of image-guided radiation therapy.
        Med Dosim. 2006; 31: 91-112
        • Yeoh E.E.
        • Holloway R.H.
        • Fraser R.J.
        • et al.
        Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial.
        Int J Radiat Oncol Biol Phys. 2006; 66: 1072-1083
        • Yokomizo A.
        • Kawamoto H.
        • Nihel K.
        • et al.
        Randomized controlled trial to evaluate radiotherapy +/− endocrine therapy versus endocrine therapy alone for PSA failure after radical prostatectomy: Japan Clinical Oncology Group Study JCOG 0401.
        Jpn J Clin Oncol. 2005; 35: 34-36
        • Zagars G.K.
        • Pollack A.
        • von Eschenbach A.C.
        Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer.
        Urology. 2001; 58: 233-239
        • Zagars G.K.
        • von Eschenbach A.C.
        • Johnson D.E.
        • et al.
        Stage C adenocarcinoma of the prostate. An analysis of 551 patients treated with external beam radiation.
        Cancer. 1987; 60: 1489-1499
        • Zagars G.K.
        • von Eschenbach A.C.
        • Johnson D.E.
        • et al.
        The role of radiation therapy in stages A2 and B adenocarcinoma of the prostate.
        Int J Radiat Oncol Biol Phys. 1988; 14: 701-709
        • Zapatero A.
        • Rios P.
        • Marin A.
        • Minguez R.
        • Garcia-Vicente F.
        Dose escalation with three-dimensional conformal radiotherapy for prostate cancer. Is more dose really better in high-risk patients treated with androgen deprivation?.
        Clin Oncol (R Coll Radiol). 2006; 18: 600-607
        • Zapatero A.
        • Valcarcel F.
        • Calvo F.A.
        • et al.
        Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
        J Clin Oncol. 2005; 23: 6561-6568
        • Zelefsky M.J.
        • Chan H.
        • Hunt M.
        • Yamada Y.
        • Shippy A.M.
        • Amols H.
        Long term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer.
        Int J Radiat Oncol Biol Phys. 2002; 53: 1111-1116
        • Zelefsky M.J.
        • Kuban D.A.
        • Levy L.B.
        • et al.
        Multi-institutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantation.
        Int J Radiat Oncol Biol Phys. 2006; ([Epub ahead of print])
        • Zietman A.L.
        Genitourinary tumors.
        in: Gunderson L.L. Tepper J.E. Clinical radiation oncology. 2nd ed. Churchill Livingstone, Philadelphia2007: 1161-1163
        • Zietman A.L.
        • DeSilvio M.L.
        • Slater J.D.
        • et al.
        Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial.
        JAMA. 2005; 294: 1233-1239

      Recommended reading

        • Aus G.
        • Abbou C.C.
        • Bolla M.
        • et al.
        EAU guidelines on prostate cancer.
        Eur Urol. 2005; 48: 546-551
        • Boehmer D.
        • Bohsung J.
        • Eichwurzel I.
        • Mois A.
        • Bubach V.
        Clinical and physical quality assurance for intensity modulated radiotherapy of prostate cancer.
        Radiother Oncol. 2004; 71: 319-325
        • Boehmer D.
        • Maingon P.
        • Poortmans P.
        • et al.
        Guidelines for primary radiotherapy of patients with prostate cancer.
        Radiother Oncol. 2006; 79: 259-269
        • Bracarda S.
        • de Cobelli O.
        • Greco C.
        • et al.
        Cancer of the prostate.
        Crit Rev Oncol Haematol. 2005; 56: 379-396
        • Dirix P.
        • Haustermans K.
        • Junius S.
        • Withers R.
        • Oyen R.
        • Van Poppel H.
        The role of whole pelvic radiotherapy in locally advanced prostate cancer.
        Radiother Oncol. 2006; 79: 1-14
        • Lee A.K.
        Radiation therapy combined with hormone therapy for prostate cancer.
        Semin Radiat Oncol. 2006; 16: 20-22
        • Morris D.
        • Emami B.
        • Mauch P.M.
        • et al.
        Evidence-based review of three-dimensional conformal radiotherapy for localized prostate cancer: an ASTRO outcomes initiative.
        Int J Radiat Oncol Biol Phys. 2005; 62: 3-19
        • Nilsson S.
        • Norlen B.J.
        • Widmark A.
        A systematic overview of radiation therapy effects in prostate cancer.
        Acta Oncol. 2004; 43: 316-381
        • Pisansky T.M.
        External-beam radiotherapy for localized prostate cancer.
        N Engl J Med. 2006; 355: 1583-1591
        • Speight J.L.
        • Roach M I.I.I.
        Radiotherapy in the management of clinically localized prostate cancer: Evolving standards, consensus, controversies and new directions.
        J Clin Oncol. 2005; 23: 8176-8185